TB CAB's proposed development pathway for regimens to treat XDR-TB
Тhe Global TB Community Advisory Board (TB CAB) releases a position paper regarding the optimal design for future evaluation of regimens for the treatment of extensively drug-resistant TB (XDR-TB).
One of the most critical scientific questions in TB today is the
optimal combination of new and repurposed drugs for the
treatment of extensively drug-resistant, pre- extensively
drug-resistant, and hard-to-treat multidrug-resistant TB
(XDR-TB, pre-XDR-TB, MDR-TB).
Тhe Global TB Community
Advisory Board (TB CAB) has developed a position paper regarding
the optimal design for future evaluation of regimens for the
treatment of XDR-TB in order to influence the direction of
discussions ongoing among stakeholders in the TB field.
The
position paper can be downloaded
here.
